CRITICAL WINDOW. A heel-prick blood test 48-72 hours after birth can detect congenital hypothyroidism | Photo Credit: Salah Uddin

India is confronting a silent, yet entirely preventable postnatal crisis. One in every 1,000 babies born in India has congenital hypothyroidism (CH), which, if left undetected, can lead to permanent intellectual disability.

CH occurs when a baby is born without a thyroid gland or an underdeveloped, or poorly functioning one. The thyroid produces thyroxine (T4), a hormone essential for brain development, growth, and metabolism. In the earliest weeks of life, thyroxine plays a decisive role in neuronal development and brain maturation. This period represents a narrow but critical window.

If adequate thyroid hormone is not available during this time, the consequences can include irreversible intellectual disability, stunted physical growth, hearing impairment, and delayed motor development. The most alarming aspect is that the affected babies almost always appear completely normal at birth. Without screening, there are no obvious clinical signs to alert families or healthcare providers.

Globally, the incidence of CH is one in 2,500-3,000 live births. In India, given the higher prevalence and the estimated 26 million births annually, each year at least 10,000 babies are born with congenital hypothyroidism, as per data with the National Neonatology Forum of India. That roughly means at least 27 babies each day and one baby each hour. Every single one of these infants has the potential to lead a normal, productive life if diagnosed and treated within two weeks after birth, through mandatory early newborn screening.

Affordable test

CH is identified using a simple heel-prick blood test conducted 48 to 72 hours after birth. The test measures thyroid stimulating hormone (TSH) levels and, when implemented at scale, costs approximately ₹50 per baby. If diagnosed promptly, the treatment involves daily oral levothyroxine, which is inexpensive, safe, and widely available. When initiated within the first 14 days of life, the treatment enables children to achieve normal intellectual and physical development. In contrast, untreated CH can reduce IQ by 30-50 points. The difference between a healthy future and lifelong disability rests on testing a single drop of blood.

The lifetime care of a child with severe intellectual disability includes special education, repeated medical consultations, rehabilitation therapies, and long-term dependency. In a country where out-of-pocket healthcare expenditure remains high, this can push households into financial distress and intergenerational disadvantage.

The next phase of progress must focus on safeguarding neurodevelopment and ensuring quality of life. Most developed nations have implemented universal newborn screening for CH for nearly six decades, virtually eliminating it as a cause of avoidable cognitive impairment. India, despite its expanding healthcare infrastructure, still lacks mandatory nationwide screening.

Universal newborn screening for CH must be integrated into all public and private birthing facilities. This requires policy mandates, structured funding, standardised testing protocols, public awareness initiatives, and centralised data monitoring systems to ensure compliance and accountability.

The science is unequivocal. The screening test is simple and affordable. The treatment is effective. What is missing is collective will. Protecting a child’s brain at birth is not optional — it is a national responsibility and a measure of our commitment to future generations.

(The writer is President, National Neonatology Forum of Karnataka. Views are personal)

More Like This

Published on March 23, 2026